Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010;59(5):1261-5.
. TRAIL shows potential cardioprotective activity. Invest New Drugs 2012;30(3):1257-60.
. TRAIL modulates the immune system and protects against the development of diabetes. J Immunol Res 2015;2015:680749.
. TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2012;13(9):1215-21.
. . Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis 2011;218(1):61-8.
. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol 2011;331(1):136-42.
. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol 2014;394(1-2):13-20.
. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases. Int J Mol Sci 2018;19(12)
. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017;18(1):219.
. Association between thyroid hormones and TRAIL. Clin Biochem 2017;50(16-17):972-976.
.